Feline Thymoma

Feline thymoma is a neoplasm arising from the epithelial cells of the thymus gland, located within the anterior (cranial) mediastinum of the cat. Although thymomas and mediastinal lymphomas represent the two most common mediastinal neoplasms in cats, thymoma is distinctly different in that it occurs predominantly in older cats, in contrast to mediastinal lymphoma which typically affects younger individuals aged approximately 2–4 years [5]. The tumor is characterized histologically by a mixture of neoplastic thymic epithelial cells and a variable population of non-neoplastic lymphocytes, and it is notably associated with a range of paraneoplastic syndromes that can complicate its clinical presentation and management [3][4]. Immunohistochemical characterization using keratin antisera has helped confirm the epithelial origin of these tumors, distinguishing them from lymphoid neoplasms [6].

Origin and Cellular Composition

Feline thymoma arises from the thymic epithelial cells of the anterior mediastinum. Using polyclonal and monoclonal keratin antisera, neoplastic stellate (epithelial) cells and Hassall's corpuscle-like structures within the tumor tissue can be positively identified, confirming the epithelial derivation of these tumors [6]. The neoplastic epithelial component is intermixed with varying numbers of small, mature, non-neoplastic lymphocytes (predominantly T lymphocytes), which has led to histological classification as lymphocytic thymoma in many reported cases [6].

Age and Epidemiology

Thymoma is almost exclusively a disease of older cats, generally diagnosed in cats over 8–9 years of age, though rare cases have been documented in younger adults [5]. The predisposing factors for malignant transformation of thymic epithelium in cats remain poorly defined, and no clear breed, sex, or environmental predispositions have been firmly established, though European Shorthair cats have been represented in reported cases [5][6].

Paraneoplastic Mechanisms

The thymus plays a central role in T-cell maturation and immune tolerance. Dysregulation of thymic immune function by the neoplastic process is believed to underlie the characteristic paraneoplastic syndromes associated with feline thymoma:

• ·Myasthenia Gravis (MG): Neoplastic thymic epithelium is thought to aberrantly present acetylcholine receptor (AChR) antigens, triggering autoantibody production against AChRs at the neuromuscular junction. This leads to impaired neuromuscular transmission and clinically manifests as generalized weakness, regurgitation from megaesophagus, and cervical ventroflexion [3].
• ·Exfoliative Dermatitis: Immune dysregulation secondary to the thymic tumor promotes autoreactive T-cell activity against epidermal structures, resulting in paraneoplastic exfoliative skin disease [1][2].
• ·Paraneoplastic Hypercalcemia: Tumor-derived humoral factors (such as PTHrP) can cause hypercalcemia by stimulating osteoclastic bone resorption and increasing renal tubular calcium reabsorption [4].

Morphological Features

Macroscopically, feline thymomas may present as cystic or solid cranial mediastinal masses [6]. Histologically, the classification is typically based on the ratio of epithelial cells to lymphocytes and on cellular atypia; lymphocyte-rich thymomas (lymphocytic thymoma) are the most commonly reported form in cats [6].

Clinical Suspicion

Any older cat presenting with respiratory distress, exercise intolerance, and evidence of a cranial mediastinal mass should be considered a thymoma candidate, particularly when accompanied by paraneoplastic signs such as muscle weakness or exfoliative dermatitis [5].

Imaging

• ·Thoracic Radiography: Typically reveals a soft-tissue opacity in the cranial mediastinum, often with pleural effusion and dorsal tracheal deviation or compression. This is usually the first diagnostic step.
• ·Thoracic Ultrasonography: Characterizes the mass as solid versus cystic, identifies pleural effusion, and guides fine-needle aspiration (FNA) or biopsy.
• ·Computed Tomography (CT): Provides the most detailed assessment of mass size, extent, vascular involvement, and surgical planning. CT is increasingly used for treatment planning.

Cytology and Histopathology

• ·Fine-Needle Aspiration (FNA): Ultrasound-guided FNA may yield a mixed population of small lymphocytes and epithelial cells, supporting a diagnosis of thymoma. However, cytology alone cannot reliably distinguish thymoma from lymphoma.
• ·Histopathology: Definitive diagnosis requires tissue biopsy (surgical or CT-guided core biopsy). Classic findings include neoplastic epithelial cells (often stellate), Hassall's corpuscle-like structures, and a background of mature small lymphocytes [6].
• ·Immunohistochemistry (IHC): Application of keratin antisera (e.g., polyclonal keratin, RCK102, RKSE60, RGE53) highlights the neoplastic epithelial cells and helps confirm thymic epithelial origin, distinguishing thymoma from mediastinal lymphoma [6].

Laboratory Findings

Routine bloodwork may reveal abnormalities reflecting paraneoplastic effects:

• ·Hypercalcemia (elevated ionized/total calcium): Due to paraneoplastic PTHrP secretion [4]; may also cause secondary azotemia.
• ·Elevated BUN / CREA: If hypercalcemia-induced nephrogenic diabetes insipidus or renal injury is present [4].
• ·Lymphocytosis or lymphopenia: Variable lymphocyte counts may reflect immune dysregulation.
• ·Hypoalbuminemia (low ALB): May occur with chronic disease, poor nutrition, or protein loss.
• ·Elevated ALT: Occasionally elevated due to hepatic involvement or systemic inflammation.
• ·Anemia (low HCT): Possible in chronic/advanced disease; rarely, immune-mediated hemolytic anemia as a paraneoplastic phenomenon.
• ·Elevated GLOB: Hyperglobulinemia may reflect immune stimulation or concurrent inflammatory disease.

Neuromuscular Testing

• ·Serum anti-AChR antibody titers: Positive in cats with paraneoplastic acquired myasthenia gravis; this finding in a cat with a mediastinal mass is highly supportive of thymoma [3].
• ·Repetitive nerve stimulation / electromyography (EMG): May demonstrate decremental response characteristic of impaired neuromuscular transmission [3].
• ·Tensilon (edrophonium) test: Short-acting acetylcholinesterase inhibitor challenge; transient improvement in weakness supports MG diagnosis [3].

Differential Diagnoses

The primary differential diagnosis is mediastinal lymphoma, which is far more common in young cats and is composed purely of neoplastic lymphoid cells without the epithelial component [5]. Other differentials include mediastinal cysts, ectopic thyroid carcinoma, and heart base tumors.

Surgical Resection (Thymectomy)

Surgical removal via median sternotomy or intercostal thoracotomy is considered the treatment of choice for resectable feline thymoma and offers the best chance of long-term control or cure [5]. Complete excision is achievable in many non-invasive thymomas. Pre-operative CT assessment is critical for determining resectability. Thorough pleural drainage prior to anesthetic induction is essential in cats with significant pleural effusion to minimize anesthetic risk.

Radiation Therapy

External beam radiotherapy is an option for incompletely resected or non-resectable thymomas. Radiation therapy may be used as an adjunct following surgery or as primary treatment in cases where surgery is declined or contraindicated. Response rates are generally favorable for epithelial-rich thymomas.

Chemotherapy

Chemotherapy is less commonly used for thymoma than for lymphoma, but may be considered in cases with invasive or malignant thymoma, or when surgical and radiation options are unavailable. Corticosteroids (prednisolone) may reduce tumor-associated lymphoid infiltration and help manage paraneoplastic immune-mediated conditions.

Management of Paraneoplastic Myasthenia Gravis

• ·Pyridostigmine bromide: Oral acetylcholinesterase inhibitor; the cornerstone of MG management to improve neuromuscular transmission [3].
• ·Immunosuppressive therapy: Prednisolone or other immunosuppressants may be required to suppress AChR autoantibody production, particularly in severe or refractory MG [3].
• ·Megaesophagus management: Elevated feeding, small frequent meals, and monitoring for aspiration pneumonia are essential supportive measures.

Management of Paraneoplastic Skin Disease

Thymectomy is reported to result in resolution or significant improvement of paraneoplastic exfoliative dermatitis after tumor removal. In the interim, immunosuppressive therapy and supportive skin care may be employed [1][2].

Management of Hypercalcemia

Intravenous fluid diuresis (0.9% NaCl), furosemide, and corticosteroids are used to manage symptomatic hypercalcemia pending definitive tumor treatment [4]. Bisphosphonates (e.g., pamidronate) may also be considered for refractory cases [4].

Pleural Effusion

Therapeutic thoracocentesis is performed as needed to relieve respiratory distress prior to and following definitive treatment.

General Prognosis

The prognosis for feline thymoma is considered guarded to fair and is highly dependent on tumor invasiveness, completeness of surgical resection, and the presence or absence of paraneoplastic complications. Feline thymomas are classified into non-invasive (encapsulated) and invasive forms; non-invasive thymomas carry a significantly better prognosis following complete surgical excision.

Surgical Outcomes

Cats undergoing complete surgical thymectomy for non-invasive thymoma generally have the most favorable outcomes, with some reports describing prolonged survival times of months to years post-operatively. The case series and case reports available in the literature, including in younger adult cats, demonstrate that surgical resection can lead to resolution of paraneoplastic signs such as exercise intolerance and respiratory compromise [5]. However, the small number of published feline cases limits precise survival statistics.

Paraneoplastic MG and Prognosis

The presence of concurrent paraneoplastic myasthenia gravis significantly complicates the prognosis. Aspiration pneumonia secondary to megaesophagus is a serious and potentially life-threatening complication that may worsen the outcome regardless of tumor control [3]. Following successful thymectomy, paraneoplastic MG may resolve, but this can take weeks to months [3].

Paraneoplastic Skin Disease

Thymoma-associated exfoliative dermatitis tends to respond to thymectomy, and resolution of skin lesions supports a favorable outcome when complete resection is achieved [1][2].

Limitations of Available Data

Formal survival statistics (median survival times, 1-year survival rates) for feline thymoma specifically are not robustly established in the referenced literature due to the rarity of the condition and the predominance of case reports and small case series rather than large prospective studies. Data on long-term prognosis is limited in current veterinary literature, and no peer-reviewed large-cohort survival statistics were identified in the references cited above. Clinicians should be aware that invasive thymoma, incomplete resection, and the development of serious paraneoplastic complications (particularly aspiration pneumonia from MG) are the most significant negative prognostic factors.

No Known Preventive Measures

Currently, there are no known vaccines, genetic screening protocols, or specific husbandry measures proven to prevent the development of feline thymoma. The etiology of malignant transformation in thymic epithelial cells remains incompletely understood, and no modifiable environmental or dietary risk factors have been established.

Early Detection

Given that thymoma occurs predominantly in older cats, routine annual or biannual veterinary wellness examinations — including thoracic auscultation and, where indicated, thoracic radiography — may facilitate earlier detection of mediastinal masses before the development of severe respiratory compromise or advanced paraneoplastic disease [5].

Monitoring of At-Risk Individuals

Older cats presenting with vague signs such as unexplained weight loss, exercise intolerance, or muscle weakness should be evaluated with thoracic imaging. Early detection and intervention before tumor invasion or severe paraneoplastic complications develop is the most practical approach to improving outcomes.